Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;5(3):184-9.
doi: 10.4103/0974-7796.115746.

Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma

Omar M Aboumarzouk  1 , Bhaskar Somani, Sarfraz Ahmad, Ghulam Nabi, Nicholas Townell, Slawomir G Kata
Affiliations

Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma

Omar M Aboumarzouk et al. Urol Ann. 2013 Jul.

Abstract

Introduction: Instillation of Mitomycin C (MMC) should prevent implantation of cancer cells released during endoscopic treatment and prevent recurrences as seen in carcinoma of the bladder.

Aim: TO DEVELOP AND EVALUATE A PROTOCOL FOR A SINGLE DOSE MMC INSTILLATION FOLLOWING HOLMIUM: YAG laser ablation of upper urinary tract transitional cell carcinoma (UUT-TCC).

Setting and design: A single institute prospective study.

Materials and methods: MMC instillations protocol was designed and offered to patients between August 2005 and April 2011. Following tumor ablation, MMC was instilled into upper urinary tract (UUT) over 40 minutes. All the patients were regularly followed up.

Results: Twenty UUT units (19 patients) were managed for UUT-TCCs using our MMC protocol. Two UUT units had G1pTa tumors, 14 had G2pTa, 2 had G3pTa, and 2 had G3pT1. At a mean follow-up of 24 months (range 1-72 months), 13/20 (65%) of the UUT units remained cancer-free, 3 (15%) UUT units developed stricture and were treated with endoscopic dilatation, only 1 (5%) of these developed long-term complications. None of the patients developed postoperative renal impairment or systemic side-effects.

Conclusions: Using a set standard protocol, MMC can safely be instilled into the UUT after TCC ablation with minimal complications or side effects, good preservation of renal function, and with a low recurrences rate comparable to the literature.

Keywords: Mitomycin C; transitional cell carcinoma; upper urinary tract; ureteroscopy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None.

Figures

Figure 1
Figure 1
Proposed algorithm for management of UT-TCC (CTU: CT Urogram, UT-TCC: Upper tract transitional cell carcinoma, URS: Ureterorenoscopy, MMC: Mitomycin C)
Figure 2a
Figure 2a
Stenosed ureter pre-dilatation
Figure 2b
Figure 2b
Dilating stenotic segment of proximal ureter with uromax 12 F balloon dilator
Figure 2c
Figure 2c
Post procedure, showing no evidence of contrast extravasation on retrograde ureteropyelogram
Figure 2d
Figure 2d
Wide ureter for endoscopic inspection 3 months following dilatation
See this image and copyright information in PMC

References

    1. Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas. 2011 Update. Eur Urol. 2011;59:584–594. - PubMed
    1. Chen GL, Bagley DH. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol. 2000;164:1173–6. - PubMed
    1. Elliott DS, Blute ML, Patterson DE, Bergstralh EJ, Segura JW. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology. 1996;47:819–825. - PubMed
    1. Lee BR, Jabbour ME, Marshall FF, Smith AD, Jarrett TW. 13-Year Survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: Equivalent outcomes. J Endourol. 1999;13:289–294. - PubMed
    1. Jarrett TW, Sweetser PM, Weiss GH, Smith AD. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol. 1995;154:1629–35. - PubMed